Dr. Jerome Coffey:

I am happy to take that. The way to look at this is that Dr. Scally's report of September 2018 set out clear recommendations which were, in effect, instructions and those are being worked on at the moment. That is all going to change in terms of HPV testing versus cytology and all the rest of it. The broader point on laboratory capacity comes back to the rate of change in science. I worked in a genetics laboratory for two years but if I went back there now, I would be fairly useless. Even since the middle of the last decade, things have changed. As such, we need to plan for a high-end diagnostics service in Ireland for cancer patients whether it is screening, germ line genetics or tumour genetic sequencing. The UK made that major investment decision a couple of years ago and is mainstreaming genomic medicine. We know what we want to do and we need to plan and invest in it quickly. That will encompass all areas of cancer diagnostics. It is an exciting time. If one looks at researchers, there is a great deal of activity in the universities here. We need to have equivalent levels of activity in the clinical services we provide to patients in the hospitals.